Glucagon Market Set to Experience Rapid Growth: Projected to Reach USD 17.26 Billion by 2034

Global Glucagon Market Overview

The Glucagon Market is on track for substantial growth, with an estimated size of USD 9.01 billion in 2024. This figure is expected to increase to USD 17.26 billion by 2034, growing at a robust CAGR of 6.72% from 2025 to 2034. The rising prevalence of diabetes, advancements in glucagon delivery systems, and increasing demand for diabetes management are key drivers behind the market's expansion.

Market Scope and Segmentation

The Glucagon Market is segmented by indication, route of administration, origin, dosage form, and region.

  • Indications: The market is primarily driven by the treatment of hypoglycemia, a severe complication of diabetes. Other segments include diabetic ketoacidosis and various lesser-known indications.

  • Route of Administration: The intravenous route holds a dominant market share, providing fast and effective delivery. Subcutaneous and intramuscular routes are also important, with expected growth in subcutaneous administration due to innovations in delivery devices.

  • Origin: Human-derived glucagon continues to dominate, but synthetic options are anticipated to rise, driven by cost-effectiveness and reduced risk of contamination.

  • Dosage Form: Injectable glucagon holds the largest share, though nasal sprays are growing in popularity due to ease of use.

Regional Analysis

The Glucagon Market is geographically diverse, with North America currently holding the largest market share. The region benefits from an established healthcare infrastructure and high diabetes prevalence. Europe follows, with notable growth in diabetes awareness and patient management. Meanwhile, Asia Pacific is poised for the highest growth, fueled by increasing healthcare expenditure and rising diabetes cases in emerging economies like China and India.

Key Market Drivers and Trends

  1. Rising Diabetes Prevalence: With 463 million adults living with diabetes in 2019, a figure expected to rise to 700 million by 2045, the demand for glucagon is growing rapidly.

  2. Technological Advancements: Innovations such as pre-filled glucagon pens and continuous glucose monitoring systems are enhancing patient convenience and improving treatment outcomes.

  3. Emergence of Biosimilars: The growing availability of biosimilar glucagon products is expected to provide more affordable treatment options, expanding the market.

  4. Telemedicine and Remote Monitoring: The increasing adoption of telemedicine for diabetes management is creating opportunities for remote glucagon delivery and real-time glucose monitoring.

Key Players

The glucagon market features significant competition from key players like Novo Nordisk, Eli Lilly and Company, Sun Pharmaceutical Industries, and Xeris Pharmaceuticals. These companies are focused on continuous innovation, with a strong emphasis on expanding product portfolios and improving patient outcomes. Eli Lilly, for instance, introduced Baqsimi, a nasal glucagon product, and continues to lead in advancing patient-friendly delivery options.

Other notable companies in the market include Biocon, KemPharm, Baxter International, Sandoz, and Teva Pharmaceutical Industries, among others.

Recent Developments and Innovations

  • Baqsimi: Eli Lilly's nasal glucagon product is making waves in the market, offering an easier-to-use alternative to traditional injections.

  • New Partnerships: Strategic collaborations between pharmaceutical companies and healthcare providers are focusing on improving accessibility and addressing emerging patient needs in diabetes care.

  • Research and Development: Ongoing investments in the development of non-injectable glucagon formulations and combination therapies are expected to further drive market growth.

Conclusion

The Glucagon Market is poised for significant growth, driven by increasing diabetes cases, technological advancements, and evolving patient preferences. The market's evolution will be shaped by a combination of innovation, strategic partnerships, and a focus on improving patient outcomes. With emerging markets showing great potential, stakeholders in the glucagon industry should remain focused on addressing the evolving demands of diabetes management while exploring new therapeutic opportunities.

About MRFR

Market Research Future (MRFR) is a global market research company that offers solutions, such as market research reports and consulting services. MRFR's team of experts delivers a comprehensive analysis and actionable insights to help businesses across industries make informed decisions.

Related MRFR Reports